StreetAlpha.app
Home › Stocks › PTCT

Ptc Therapeutics, Inc. (PTCT)

Healthcare
$56.42
▼ −3.27%
LAST CLOSE · NOV 20

PTC Therapeutics develops and markets prescription drugs, including Sephience and Emflaza, for patients treated by doctors. It last closed at $56.42 on Nov 20, down 3.27% on the day. The next earnings report for PTCT is expected around Mon, Jan 11, 2027, after the close. For the quarter ended Sep 2026, PTCT reported EPS of -$0.62 on revenue of $357.8M, with revenue up 69.6% from a year ago. Over its last 8 reports the stock moved an average of 7.9% the session after earnings. Over the last 12 months PTCT insiders bought $0 of stock on the open market and sold $56.2M, according to SEC Form 4 filings.

AI Auto Pilots
Is PTCT in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold PTCT.

Key Stats

Last 12 months
Results
Revenue
$1.2B
−35.1% vs a year ago
Net income
−$106.0M
−114.1% vs a year ago
EPS (diluted)
−$1.33
−115.5% vs a year ago
Free cash flow
$2.1M
0.2% margin
Valuation
Market cap
$4.7B
83.5M shares
P/E
–
No P/E while losing money
Price to sales
4.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$508.9M
At Sep 30
Debt
$536.3M
At Sep 30
Shareholder equity
−$191.2M
Shares outstanding
83.5M
At Oct 27
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $538.6M$538.6MFY2021FY2022: $698.8M$698.8MFY2022FY2023: $937.8M$937.8MFY2023FY2024: $806.8M$806.8MFY2024FY2025: $1.7B$1.7BFY2025

From PTCT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 29). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · After the close
Reported EPS
-$0.62
Quarter ended Sep 2026
Year ago EPS
$0.20
−410.0% on a GAAP basis
Revenue
$357.8M
+69.6% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.85Dec '24Mar 2025: $10.04Mar '25Jun 2025: -$0.83Jun '25Sep 2025: $0.20Sep '25Dec 2025: -$1.67Dec '25Mar 2026: -$0.03Mar '26Jun 2026: $0.92Jun '26Sep 2026: -$0.62Sep '26Latest -$0.62
Revenue by quarter
Dec 2024: $213.2MDec '24Mar 2025: $1.18BMar '25Jun 2025: $178.9MJun '25Sep 2025: $211.0MSep '25Dec 2025: $164.7MDec '25Mar 2026: $272.6MMar '26Jun 2026: $360.5MJun '26Sep 2026: $357.8MSep '26Latest $357.8M
How PTCT moved after its last 8 reports
Average move the session after a report ±7.9%
Oct 29, 2026After the close−7.0%
Jul 30, 2026After the close−9.9%
May 7, 2026After the close+14.3%
Feb 19, 2026After the close+1.1%
Jan 12, 2026After the close−2.8%
Nov 4, 2025After the close+6.0%
Aug 7, 2025After the close−9.9%
May 6, 2025After the close+12.6%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on PTCTStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on PTCT
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on PTCT

Technical Analysis

PTCT · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 11% below its 20 day and 12% below its 50 day average. It is 24% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 34), near oversold. The nearest support is the 52 week low at $56.18, and the nearest resistance the Pivot at $57.19.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 4.3%/day
Key levels
$90.8752 week high+61.1%
$69.79200 day average+23.7%
$68.95100 day average+22.2%
$63.74Swing high (Oct 21)+13.0%
$63.2650 day average+12.1%
$62.8520 day average+11.4%
$58.19Pivot R1+3.1%
$57.19Pivot+1.4%
$56.42Last close
$56.1852 week low−0.4%
$55.41Pivot S1−1.8%
Indicators
RSI (14)33.59Weak, oversold below 30Neutral
MACD-1.25Below its signal lineBearish
Stochastic5.1Near the bottom of its rangeOversold
ADX (14)17.2No clear trend
Williams %R-98.3Oversold below −80, overbought above −20Oversold
CCI (20)-161.6Oversold below −100, overbought above 100Oversold
Rate of change−13.8%Change over 10 sessionsBearish
ATR (14)$2.45Typical daily range, 4.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PTCT

What happened before

See how PTCT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow PTCT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How PTCT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for PTCTHow many large options trades hit PTCT, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

PTCT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▼179 buying vs 210 selling
  • ▼Held by funds -24.1 pts
  • ▼Funds holding -25
  • ▲Superinvestors: 3 added, 2 cut
  • ▲Put/call 0.04 to 0.01
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding361386−6.5%
In funds' top 1057−28.6%
Held by funds113.1%137.2%−24.1 pts
New / increased55 / 12475 / 142−17.5%
Reduced / sold out134 / 76113 / 45+32.9%
Put/call ratio0.010.04−84.5%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PTCT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

PTCT Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$56.2M68 sales · 13 insiders
100% of the selling was under pre-arranged trading plans.
2025-12 sold $5.8M2026-01 sold $4.7M2026-02 sold $2.1M2026-03 sold $2.5M2026-04 sold $4.0M2026-05 sold $1.4M2026-06 sold $8.8M2026-07 sold $6.5M2026-08 sold $4.5M2026-09 sold $3.5M2026-10 sold $453K2026-11 sold $174KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 16Mark Elliott BouldingExec. VP And CloSale plan2,812$61.88$174K
Oct 14Michael SchmertzlerDirectorSale plan2,500$59.61$149K
Oct 9Mark Elliott BouldingExec. VP And CloSale plan192$64.26$12K
Oct 7Michael SchmertzlerDirectorSale plan2,500$63.39$158K
Oct 6Mark Elliott BouldingExec. VP And CloSale plan2,073$64.06$133K
Sep 30Glenn Steele Jr Md PhdDirectorSale plan12,000$65.16$782K
Every insider buy and sale for PTCT over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See PTCT insider trades →

From SEC Form 4 filings by PTCT's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PTCT is in one of them and how their past PTCT trades turned out.

PTCT in the AI portfolios
Loading…

PTCT News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PTCT in an article yet. Here's the latest on the wider market.

PTCT in the news

About Ptc Therapeutics

PTC Therapeutics is a pharmaceutical company based in Warren, New Jersey. It develops and markets prescription drugs, including Sephience and Emflaza, and its products are often for conditions that affect a small number of patients. Sales depend heavily on coverage and reimbursement from government programs such as Medicare and Medicaid and from private insurers, as well as on physician prescribing.

Headquarters
Warren, NJ
Founded
1998